Ninlaro (ixazomib) / Takeda  >>  Phase 1
Welcome,         Profile    Billing    Logout  

36 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ninlaro (ixazomib) / Takeda
NCT02176486: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Terminated
1b
12
US, Europe, RoW
Ixazomib, MLN9708, Placebo
Takeda
Lupus Nephritis
03/17
01/18
NCT03770260: Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Completed
1b
8
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924
National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
09/22
07/23
NCT03783416: SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Recruiting
1b
72
Europe
Ixazomib (NINLARO®) capsules / Matching placebo capsules
Queen Mary University of London, Takeda Pharmaceuticals International, Inc.
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
08/23
08/23
NCT00830869: A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Completed
1
116
Canada, US
IXAZOMIB
Millennium Pharmaceuticals, Inc.
Advanced Non-hematologic Malignancies
04/12
04/12
NCT00963820: Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Checkmark P1 data at ASH
Nov 2011 - Nov 2011: P1 data at ASH
Checkmark P1 data at ASH
Nov 2011 - Nov 2011: P1 data at ASH
Checkmark Data
More
Completed
1
60
US
Ixazomib citrate, MLN9708
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/12
01/14
NCT00932698: Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Completed
1
60
US
Ixazomib, MLN9708
Millennium Pharmaceuticals, Inc.
Relapsed and Refractory Multiple Myeloma
06/13
05/17
NCT01645930: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Checkmark EHA 2014
May 2014 - May 2014: EHA 2014
Completed
1
43
RoW
Ixazomib, Lenalidomide, Dexamethasone
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
07/14
04/17
NCT00893464: A Study of IXAZOMIB in Adult Patients With Lymphoma

Completed
1
31
US, Canada
IXAZOMIB
Millennium Pharmaceuticals, Inc.
Lymphoma
10/14
10/14
NCT01953783: Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Completed
1
7
US
IXAZOMIB
Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors, Lymphoma
12/14
02/16
NCT01912222: Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

Completed
1
48
US
IXAZOMIB
Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors, Hematologic Malignancies
03/15
03/15
NCT01830816: Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Completed
1
41
Canada, US
Ixazomib, MLN9708
Millennium Pharmaceuticals, Inc.
Multiple Myeloma, Advanced Solid Tumors
03/15
11/16
NCT01454076: Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Completed
1
112
US
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Millennium Pharmaceuticals, Inc.
Nonhematologic Malignancies, Lymphoma
04/15
06/16
NCT01887587: Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated
1
5
US
MLN9708, Ixazomib, Vincristine, Oncovin, Doxorubicin, Doxil, hydroxydaunorubicin, Dexamethasone, Decadron, Dexasone, Solurex, Baycadron
Ehab L Atallah
Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
02/16
02/16
NCT02228772: Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Completed
1
19
US
MLN 9708, Ixazomib, Vincristine, Oncovin, Vincasar PFS, Vincrex, Vincristine sulfate, VCR, Cytarabine, Ara-C, Cytosar-U, Cytosine arabinoside, Doxorubicin, Adriamycin, Rubex, Mercaptopurine, 6-MP, Purinethol, Purixan, Cyclophosphamide, Cytoxan, Neosar, CTX, Methotrexate, Folex, Mexate, MTX, Methotrex (formerly Amethopterin)
Massachusetts General Hospital, Millennium Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
10/16
11/19
NCT02070458: Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Completed
1
30
US
ixazomib, MLN9708, proteasome inhibitor MLN9708, mitoxantrone hydrochloride, CL 232315, DHAD, DHAQ, Novantrone, etoposide, EPEG, VP-16, VP-16-213, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
03/17
08/17
NCT03422874: Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

Withdrawn
1
0
US
MLN9708, Ixazomib, Nelfinavir, Viracept
Dartmouth-Hitchcock Medical Center
Neoplasms, Lymphoma
08/17
08/17
NCT02578511: Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Withdrawn
1
0
US
Ixazomib
Ehab L Atallah
Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
02/18
02/18
NCT02384746: Phase I Study of the Combination of MLN9708 and Fulvestrant

Terminated
1
9
US
Fulvestrant, Faslodex, MLN9708, Ixazomib
Dartmouth-Hitchcock Medical Center
Breast Cancer
04/18
06/18
NCT02630030: Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

Completed
1
3
US
Ixazomib, MLN9708
Emory University, Takeda
Glioblastoma
07/18
09/20
NCT01318902: Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Completed
1
27
Europe, Canada, US
Ixazomib, MLN9708, Dexamethasone
Millennium Pharmaceuticals, Inc.
Light-Chain Amyloidosis
11/18
11/18
NCT04272775: A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Terminated
1
14
NA
Ixazomib, MLN9708, Lenalidomide, Dexamethasone
Takeda
Relapsed and/or Refractory Multiple Myeloma
02/19
02/19
NCT02042989: MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Completed
1
68
US
MLN9708, Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Advanced Cancers
01/20
01/20
NCT02504359: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Completed
1
11
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N''-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Quality-of-Life Assessment, Quality of Life Assessment, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
OHSU Knight Cancer Institute, Oregon Health and Science University
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
09/20
09/20
2018-003907-20: Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Relapsed or Refractory Lymphoblastic Lymphoma Estudio para evaluar la dosis máxima tolerada, la farmacocinética y la seguridad de ixazomib administrado por vía intravenosa a pacientes pediátricos con leucemia linfoblástica aguda en recaída o resistente o linfoma linfoblástico recidivante o refractario

Not yet recruiting
1
18
Europe
Ixazomib, Powder for solution for injection
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit, Millennium Pharmaceuticals, Inc.
Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma Leucemia linfoblástica aguda en recaída o resistente y linfoma linfoblástico en recaída o resistente, Cancer Cancer, Diseases [C] - Cancer [C04]
 
 
NCT02831686: A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Completed
1
18
US
Selinexor, (KPT-330), Ixazomib, Dexamethasone
Memorial Sloan Kettering Cancer Center, Karyopharm Therapeutics Inc, Millennium Pharmaceuticals, Inc.
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
11/20
11/20
NCT03880123: Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Withdrawn
1
0
US
Selinexor, KPT-330, Ixazomib, Ninlaro
Matthew Ingham, Karyopharm Therapeutics Inc, Takeda
Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
11/20
11/20
NCT03399539: Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed
1
7
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Mayo Clinic, Multiple Myeloma Research Foundation
Recurrent Plasma Cell Myeloma, t(11;14)
12/21
02/24
NCT02921893: Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Active, not recruiting
1
21
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Plasmacytoma, POEMS Syndrome
03/22
10/24
NCT02582359: MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

Completed
1
39
US
MLN9708, Ixazomib, Cytarabine, Cytosar-U®, Ara-C, Arabinosylcytosine, Daunorubicin, Cerubidine®
Massachusetts General Hospital, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/22
04/22
NCT03888534: Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

Withdrawn
1
0
Europe, US
Ixazomib, MLN9708
Millennium Pharmaceuticals, Inc.
Precursor Cell Lymphoblastic Leukemia-lymphoma
08/22
08/22
NCT02942095: Study of Ixazomib and Erlotinib in Solid Tumors

Completed
1
9
US
Ixazomib, MLN9708, Erlotinib, Erlotinib Hydrochloride, OSI-774, CP358774, Tarceva
M.D. Anderson Cancer Center, Millennium: The Takeda Oncology Company
Solid Tumors
12/22
12/22
NCT02697383: Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Completed
1
14
US
Ixazomib (MLN9708), Dexamethasone
Memorial Sloan Kettering Cancer Center, Millennium Pharmaceuticals, Inc.
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
05/24
05/24
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/24
07/25
NCT04847453: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Recruiting
1
24
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Transabdominal Ultrasound, abdominal ultrasound, TUS, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
AL Amyloidosis
06/26
06/26
NCT03283917: Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Active, not recruiting
1
21
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib, MLN-2238, MLN2238
M.D. Anderson Cancer Center, Janssen Pharmaceuticals, Takeda
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
05/25
05/25
evaluation of the safety, tolerability, pharmacokinetic characteristics, and efficacy of Bisthianostat tablets combined with Ixazomib and Dexamethasone in patients with relapsed or refractory multiple myeloma, ChiCTR2300068144: Phase Ⅰ b clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of Bisthianostat tablets combined with Ixazomib and Dexamethasone in patients with relapsed or refractory multiple myeloma

Not yet recruiting
1
54
 
100mg Bisthianostat + 4mg Ixazomib + 20mg Dexamethasone ;200mg Bisthianostat + 4mg Ixazomib + 20mg Dexamethasone ;400mg Bisthianostat + 4mg Ixazomib + 20mg Dexamethasone ;600mg Bisthianostat + 4mg Ixazomib + 20mg Dexamethasone ;X mg Bisthianostat + 4mg Ixazomib + 20mg Dexamethasone
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, SHANGHAI THEORION PHARMACEUTICAL CO., LTD
Recurrent or refractory multiple myeloma
 
 

Download Options